Companies
Company news
Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first. Each one links to the filing or release it was written from.Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first.
3 articles on SMMT
-
Summit Therapeutics to feature ivonescimab data at ESMO 2026
The company said the data will be presented in numerous presentations across multiple tumor types at the congress in Madrid, Spain.
-
Summit Therapeutics enters ivonescimab trial collaboration with ECOG-ACRIN
The Phase II/III study evaluates ivonescimab, an investigational bispecific antibody, in first-line biliary tract cancer.
-
Summit Therapeutics opens global Phase II ivonescimab study in kidney cancer
The multiregional study is testing ivonescimab-based regimens in patients who have not had prior treatment for their cancer.
How these are written
- The source: the company's own 8-K filing or press release, linked from every article. What the company says is attributed to the company.
- The checks: each article is written by GetSignal with AI and checked against its source before it is shown.
- The date: the day the company filed the 8-K or published the release.
- Not investment advice. An article reports what the company disclosed; it is not a view on the stock.
Follow companies on GetSignal
Their filings, insider trades and company news in one feed. Free on iPhone and Android.
